RS71304A - Microlia inhibitors for iterrupting immune reactions inducted by interleukin 12 and ifn$(g) - Google Patents

Microlia inhibitors for iterrupting immune reactions inducted by interleukin 12 and ifn$(g)

Info

Publication number
RS71304A
RS71304A YU71304A YUP71304A RS71304A RS 71304 A RS71304 A RS 71304A YU 71304 A YU71304 A YU 71304A YU P71304 A YUP71304 A YU P71304A RS 71304 A RS71304 A RS 71304A
Authority
RS
Serbia
Prior art keywords
inhibitors
microlia
iterrupting
inducted
ifn
Prior art date
Application number
YU71304A
Other languages
Serbian (sr)
Inventor
Thorsten Blume
Wolf-Dietrich Docke
Wolfgang Halfbrodt
Joachim Kuhnke
Ursula Moning
Bernd Elger
Herbert Schneider
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of RS71304A publication Critical patent/RS71304A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to the use of microglia inhibitors for producing medicaments that inhibit the monocyte, macrophage and T cell- induced immune reactions, and to their use for treating T cell-induced immunological diseases and inflammatory reactions that are not T-cell induced.
YU71304A 2002-02-15 2003-01-17 Microlia inhibitors for iterrupting immune reactions inducted by interleukin 12 and ifn$(g) RS71304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (en) 2002-02-15 2002-02-15 Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses
PCT/EP2003/000467 WO2003068225A1 (en) 2002-02-15 2003-01-17 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Publications (1)

Publication Number Publication Date
RS71304A true RS71304A (en) 2006-10-27

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
YU71304A RS71304A (en) 2002-02-15 2003-01-17 Microlia inhibitors for iterrupting immune reactions inducted by interleukin 12 and ifn$(g)

Country Status (21)

Country Link
EP (1) EP1474138A1 (en)
JP (1) JP2005522447A (en)
KR (1) KR20040084909A (en)
CN (1) CN1756546A (en)
AR (1) AR039556A1 (en)
AU (1) AU2003245523A1 (en)
BR (1) BR0307706A (en)
CA (1) CA2475770A1 (en)
DE (1) DE10207843A1 (en)
EC (1) ECSP045297A (en)
MX (1) MXPA04007943A (en)
NO (1) NO20043840L (en)
PE (1) PE20030906A1 (en)
PL (1) PL371327A1 (en)
RS (1) RS71304A (en)
RU (1) RU2004127677A (en)
TW (1) TW200306823A (en)
UA (1) UA81111C2 (en)
UY (1) UY27662A1 (en)
WO (1) WO2003068225A1 (en)
ZA (1) ZA200407382B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (en) * 2002-02-15 2003-09-04 Schering Ag 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives
WO2006097547A1 (en) * 2005-03-17 2006-09-21 Proyecto De Biomedicina Cima S.L. Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
BR112014030940B1 (en) * 2012-06-11 2022-09-06 UCB Biopharma SRL BENZIMIDAZOLS THAT MODULATE TNF-ALFA AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
PL3371190T3 (en) 2015-11-06 2022-11-07 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
PL3390367T3 (en) * 2015-12-15 2021-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
AR107293A1 (en) 2016-01-05 2018-04-18 Incyte Corp PIRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-g INHIBITORS
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JP7244504B2 (en) 2017-10-18 2023-03-22 インサイト・コーポレイション Fused Imidazole Derivatives Substituted with Tertiary Hydroxy Groups as PI3K-γ Inhibitors
CR20210165A (en) 2018-09-05 2021-10-01 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
FI3860998T3 (en) 2018-10-05 2024-03-27 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity
CN112341451B (en) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 Immunomodulator
CN112341450B (en) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 Immunomodulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (en) * 1993-09-09 1995-03-16 Schering Ag New benzimidazole derivatives, processes for their preparation and their pharmaceutical use
MXPA02005742A (en) * 2000-01-14 2002-09-18 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation.
DE10134775A1 (en) * 2001-07-06 2003-01-30 Schering Ag 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
AR039556A1 (en) 2005-02-23
NO20043840L (en) 2004-11-12
UY27662A1 (en) 2003-09-30
DE10207843A1 (en) 2003-09-04
ZA200407382B (en) 2005-09-14
EP1474138A1 (en) 2004-11-10
CN1756546A (en) 2006-04-05
KR20040084909A (en) 2004-10-06
JP2005522447A (en) 2005-07-28
ECSP045297A (en) 2004-10-26
CA2475770A1 (en) 2003-08-21
MXPA04007943A (en) 2004-11-26
WO2003068225A1 (en) 2003-08-21
TW200306823A (en) 2003-12-01
BR0307706A (en) 2005-01-11
RU2004127677A (en) 2005-06-10
UA81111C2 (en) 2007-12-10
PE20030906A1 (en) 2004-01-17
PL371327A1 (en) 2005-06-13
AU2003245523A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
RS71304A (en) Microlia inhibitors for iterrupting immune reactions inducted by interleukin 12 and ifn$(g)
MXPA03008955A (en) Remedies for infant chronic arthritis-relating diseases.
BR9808998A (en) Substituted imidazoles useful in the treatment of inflammatory diseases
NO20016007D0 (en) Recombinant anti-CD40 antibody and uses thereof
ES2151467T1 (en) INHIBITION OF THE ACTIVITY OF QUINASA P38 BY ARIL-UREAS.
FI963101A0 (en) Use of anti-TNF antibodies as drugs for the treatment of diseases in which serum interleukin-6 levels are elevated
MXPA05011266A (en) Methods for treating interleukin-6 related diseases.
DE69836563D1 (en) INHIBITION OF p38 KINASE ACTIVITY BY THE USE OF ARYL AND HETEROARYL SUBSTITUTED UREAS
HK1040493A1 (en) Use of mammalian cytokine synthesis inhibitory factor in manufacturing a medicament.
GB0209891D0 (en) Novel compounds
ES2154253T1 (en) INHIBITION OF THE ACTIVITY OF QUINASA P38 USING REPLACED HETEROCICLICAL UREAS.
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
PT814831E (en) MEDICATIONS FOR THE TREATMENT OF AUTOIMUNITARY DISEASES USING TAU INTERFERENCE
IT1245712B (en) USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
MY138373A (en) Cytokine inhibitors
MY111402A (en) Novel uses of il-4 and/or il-10, and antibodies against the same
TR199900318T2 (en) IL-8 receptor antagonists.
ATE520669T1 (en) 1,2-DIARYLBENZIMIDAZOLE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH MICROGLIA ACTIVATION
UY28080A1 (en) POSITIONAL ISOMERS OF IFN PEG ALFA 2A
DK1082131T3 (en) Immunoregulator
Mizuno et al. β2-Adrenergic receptor stimulation inhibits LPS-induced IL-18 and IL-12 production in monocytes
NO932377D0 (en) ANTIVIRAL RELATIONS
EP0668774A4 (en) Interleukin receptor targeted molecules for treatment of inflammatory arthritis.
MX9708416A (en) Piperazino derivatives as neurokinin antagonists.
AU2003265924A1 (en) Benzimidazolones and their use as cytokine inhibitors